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Abstract
Background: Obesity is associated with increased risks for development of cardiovascular diseases. Epidemiological studies
report an inverse association between dietary flavonoid consumption and mortality from cardiovascular diseases. We
studied the potential beneficial effects of dietary supplementation of red wine polyphenol extract, ProvinolsTM, on obesity-
associated alterations with respect to metabolic disturbances and cardiovascular functions in Zucker fatty (ZF) rats.
Methodology/Principal Findings: ZF rats or their lean littermates received normal diet or supplemented with ProvinolsTM
for 8 weeks. ProvinolsTM improved glucose metabolism by reducing plasma glucose and fructosamine in ZF rats. Moreover,
it reduced circulating triglycerides and total cholesterol as well as LDL-cholesterol in ZF rats. Echocardiography
measurements demonstrated that ProvinolsTM improved cardiac performance as evidenced by an increase in left ventricular
fractional shortening and cardiac output associated with decreased peripheral arterial resistances in ZF rats. Regarding
vascular function, ProvinolsTM corrected endothelial dysfunction in aortas from ZF rats by improving endothelium-
dependent relaxation in response to acetylcholine (Ach). ProvinolsTM enhanced NO bioavailability resulting from increased
nitric oxide (NO) production through enhanced endothelial NO-synthase (eNOS) activity and reduced superoxide anion
release via decreased expression of NADPH oxidase membrane sub-unit, Nox-1. In small mesenteric arteries, although
ProvinolsTM did not affect the endothelium-dependent response to Ach; it enhanced the endothelial-derived
hyperpolarizing factor component of the response.
Conclusions/Significance: Use of red wine polyphenols may be a potential mechanism for prevention of cardiovascular and
metabolic alterations associated with obesity.
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Introduction
Obesity is a fast growing problem that is reaching epidemic
proportions worldwide, and is associated with an increased risk of
premature death [1]. Individuals with a central deposition of
adipose tissue display elevated cardiovascular morbidity and
mortality, including stroke, congestive heart failure, myocardial
infarction and cardiovascular death, and this is independent of the
association between obesity and other cardiovascular risk factors
[2]. Obesity, in particular abdominal obesity, was pointed out as a
primary contributor to acquired insulin resistance, as increasing
adiposity is correlated with impaired insulin action [3]. Endothelial
dysfunction, an independent predictor of cardiovascular events
[4], has been consistently associated with obesity and the
metabolic syndrome [5] in a complex interplay with insulin
resistance [6]. Deficiency of endothelial nitric oxide (NO) is
believed to be the primary defect that links insulin resistance and
endothelial dysfunction [7].
Epidemiological studies report an inverse association between
dietary polyphenol consumption and mortality from cardiovascu-
lar diseases [8]. In the past decade, red wine polyphenolic
compounds, including ProvinolsTM, have been shown to exert
numerous biological effects that might participate in cardio- and
vasculo-protection. Polyphenols possess anti-aggregatory platelet
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activity, antioxidant and free radical scavenging properties [9,10].
Furthermore, red wine and its polyphenolic constituents possess
lipid- and lipoprotein-lowering effects [9]. Moreover, ProvinolsTM
is a powerful vasodilator through the generation of NO and can
act on the expression of genes protective of the cardiovascular
system [11]. Due to these pleiotropic properties, polyphenols may
be good candidates to correct metabolic and cardiovascular
alterations associated with obesity and metabolic syndrome.
In the present work, we studied the potential beneficial effects of
dietary supplementation of the red wine polyphenol extract,
ProvinolsTM, in an experimental model of obesity and metabolic
syndrome with an emphasis on glucose and lipid metabolisms,
cardiac and endothelial functions. Of particular interest is to study
the cellular pathways related to nitrosative and oxidative stresses in
blood vessels. For this purpose, we used the Zucker fatty (ZF) rat, a
widely used animal model of obesity and type 2 diabetes, which
presents many of the human metabolic syndrome features such as
insulin resistance, dyslipidemia, hyperinsulinemia [12,13] and, in
some colonies, hypertension that develops by 4–5 months of age
[14]. On the other hand, their lean littermates are insulin-sensitive,
normoinsulinemic, normotensive, and have normal lipid profiles
and glucose tolerance. Furthermore, this model presents a loss of
functional mutation in the leptin receptor [15,16].
Methods
Animals and experimental protocol
The university of Angers ethical committee approved the
present protocol. All animal studies were carried out using
approved institutional protocols and were conformed the Guide
for the Care and Use of Laboratory Animals published by US National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
Twenty-four ZF rats and twelve of their lean littermate non-obese
rats (Charles River; L’Arbresle, France) received for eight weeks
either a control diet or a diet containing ProvinolsTM (Socie´te´
Franc¸aise de Distilleries; Vallon Pont d’Arc, France) at the dose of
20 mg/kg/day. The dose of ProvinolsTM was described to induce
cardiovascular effects, including improvement of endothelial
function [17] and prevention of the increase in blood pressure in
NO-deficient hypertensive rats [18] and protection of both cardiac
ischemia [19] and stroke [20]. Eight weeks of treatment has been
reported to protect against deleterious effects of hypertension [21]
and chronic-stress exposure [22].
Measurement of blood pressure
Blood pressure was measured using the tail-cuff technique
weekly. Each rat was trained to the tail-cuff technique for 2 days
before each measurement recorded with a Physiograph Desk
Model and an Electro-Sphygmomanometer (BIOSEB; Paris,
France). Five separate measurements were made on conscious
rats for systolic blood pressure and heart rate determinations.
Echocardiographic examination
Transthoracic echocardiography was performed using an ATL-
HDI 5500 ultrasound machine equipped with a 8-MHz imaging
transducer in rats anesthetized with pentobarbital sodium (50 mg/
kg ip). Briefly, a two-dimensional short axis view of the left
ventricle was obtained at the level of the papillary muscle in order
to record M-mode tracings. Diastolic left ventricular dimension
(LVDd) and systolic left ventricular dimension (LVDs) were
measured by the American Society of Echocardiology leading-
edge method from at least 3 consecutive cardiac cycles. Doppler
cardiac output was calculated by the following formula: Cardiac
output = 6D2/46IVTAo, where D represents the diameter of
the aortic left ventricular outflow tract and IVTAo the velocity-
time integral in the left ventricular outflow tract. Also, total arterial
peripheral resistances were calculated from blood pressure and
cardiac output.
Circulating parameters measurement
Rats were anesthetized with isoflurane and blood was harvested
from abdominal aorta. The plasma was separated for circulating
glucose, fructosamine, total cholesterol, low density lipoprotein
(LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol,
triglycerides, creatinin, and uric acid analysis (technical platform
of Toulouse Midi-Pyre´ne´es GenopoleH IFR31; Toulouse, France).
Vascular reactivity
Aortic and small mesenteric artery (SMA) rings (1.5–2 mm long)
were obtained from ZF and lean rats having received ProvinolsTM
or a vehicle. Then, they were mounted on a wire myograph
(Danish MyoTechnology, Aarhus, Denmark) filled with physio-
logical salt solution (PSS) as previously described [23]. Endothe-
lium-dependent vasodilatation in response to acetylcholine (Ach,
1 nM to 10 mM) was studied in aortas and SMA with functional
endothelium pre-contracted with the thromboxane A2 agonist (9,
11-dideoxy-11a, 9a-epoxymethanoprostaglandin F2-a) U46619
(Sigma-Aldrich; St. Quentin, Fallavier, France) at 80% of their
maximal response. In SMA from ZF rats the different components
of the vaso-relaxation were determined as follows: the NO-
dependent dilation was measured in the presence of a non selective
cyclo-oxygenase (COX) inhibitor, indomethacin, (INDO,
100 mM; Sigma-Aldrich), apamin (100 nM; Sigma-Aldrich) and
charybdotoxin (50 nM; Sigma-Aldrich). The endothelium-derived
hyperpolarizing factor (EDHF) component was assessed in the
presence of the NO synthase inhibitor Nv-Nitro-L-arginine methyl
ester (L-NAME, 100 mM; Sigma-Aldrich) and INDO (100 mM).
Nitric oxide (NO) and superoxide anion (O2
2)
determination by electron paramagnetic resonance (EPR)
Aortas, carotid arteries and SMA were dissected and incubated
for NO production for 30 min in Krebs–Hepes buffer containing:
BSA (20.5 g/L), CaCl2 (3 mM) and L-Arginine (0.8 mM) (Sigma-
Aldrich). NaDETC (1.5 mM) and FeSO4.7H2O (1.5 mM) (Sigma-
Aldrich) were separately dissolved under argon gas bubbling in
10 mL volumes of ice-cold Krebs–Hepes buffer. These were
rapidly mixed to obtain a pale yellow-brown opalescent colloid
Fe(DETC)2 solution (0.4 mM), which was used immediately. The
colloid Fe(DETC)2 solution was added to vessels and incubated for
45 minutes at 37uC. Then, arteries were immediately frozen in
plastic tubes using liquid N2. NO measurement was performed on
a table-top x-band spectrometer Miniscope (Magnettech, MS200;
Berlin, Germany). Recordings were made at 77uK, using a Dewar
flask. Instrument settings were 10 mW of microwave power, 1 mT
of amplitude modulation, 100 kHz of modulation frequency, 150 s
of sweep time and 3 scans. Signals were quantified by measuring
the total amplitude, after correction of baseline as done previously
[23]. Values are expressed in unit/mg weight of dried tissue.
For O2
2 spin-trapping, aortas, carotid arteries and SMA were
dissected and allowed to equilibrate in deferoxamine-chelated
Krebs-Hepes solution containing 1-hydroxy-3methoxycarbonyl-
2,2,5,5-tetramethylpyrrolidin (CMH, Noxygen; Denzlingen, Ger-
many) (500 mM), deferoxamin (25 mM, Sigma-Aldrich) and
DETC (5 mM, Sigma-Aldrich) under constant temperature
(37uC) for 60 minutes. Then, they were frozen in liquid N2 and
analyzed in a Dewar flask by EPR. Values are expressed in unit/
mg weight of dried tissue.
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Western Blotting
Aorta was dissected, homogenized and lysed. Proteins (80 mg)
were separated on 10% SDS-PAGE. Blots were probed with anti-
endothelial NOS (eNOS), anti-phospho-eNOS Ser 1177, anti-
phospho-eNOS Thr 495 (Cell Signaling; Beverly, MA), anti-
caveolin-1 (BD Biosciences; San Jose, CA), Mn-superoxide
dismutase (SOD), Cu/Zn-SOD, extracellular (Ec)-SOD (Stressgen
Biotechnologies Corporation; Victoria, Canada), anti-gp91phox
(Nox-2; BD Biosciences), anti-Nox-1 and anti-Nox-4 antibodies.
Data analysis
Data are expressed as mean6SEM, and n represents the
number of experiences. Statistical analyses were performed using a
one way analysis of variance (ANOVA), and Mann-Whitney U
tests or ANOVA for repeated measures and subsequent Bonfer-
roni post hoc test. P,0.05 was considered to be statistically
significant.
Results
ProvinolsTM improve circulating parameters in ZF rats
ZF rats weighed significantly more than their lean controls and
ProvinolsTM treatment did not affect body weight of either group
(data not shown).
As expected, ZF rats exhibited high glucose and fructosamine
levels compared to their lean littermates (Figure 1A, 1B).
Interestingly, ProvinolsTM normalized both glycemia and fructo-
samine levels in ZF rats, suggesting an improvement in whole-
body glucose homeostasis [24]. In addition, ZF rats displayed a
high circulating level of total cholesterol (Figure 1C) as well as an
elevated ratio between LDL- and HDL-cholesterol (Figure 1D)
compared to lean rats. Interestingly, these two parameters were
significantly improved by the ProvinolsTM treatment in ZF rats.
Moreover, ZF rats exhibited high levels of circulating triglycerides
compared to lean littermates (Figure 1E), and ProvinolsTM
treatment significantly reduced triglyceride level in these animals.
Figure 1. ProvinolsTM improve metabolic parameters in ZF rats. Circulating levels of glucose (A), fructosamine (B), total cholesterol (C), ratio
between LDL- and HDL-cholesterol (D), triglygerides (E), creatinin (F) and uric acid (G) were evaluated in fasting plasma of rats. Values are
means6SEM (n=11–12). *P,0.05, **P,0.01, ***P,0.001 Zucker fatty (ZF) rats vs. lean rats; #P,0.05, ###P,0.001 ZF+ProvinolsTM rats vs. ZF rats.
doi:10.1371/journal.pone.0005557.g001
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Finally, we observed that ZF rats exhibited increased levels of
creatinin (Figure 1F) and uric acid (Figure 1G) compared to their
lean controls, and while ProvinolsTM did bit affect the uric acid
levels, it reduced the creatinin levels to those measured in lean
controls (Figure 1F).
ProvinolsTM improve cardiac parameters in ZF rats
We investigated the structure and function of the left ventricle of
ZF compared to their lean littermates by echocardiography and
assessed the effect of ProvinolsTM (Figure 2). We found that ZF rats
displayed a reduced diastolic left ventricular dimension (LVDd)
(Figure 2A) compared to lean controls, even though the systolic left
ventricular dimension (LVDs) remained the same (Figure 2B).
Interestingly, ProvinolsTM reduced LVDs without affecting LVDd
in ZF rats compared to the lean littermates (Figure 2A and 2B), and
thus, increased left ventricular fractional shortening.
Moreover, we observed that although the ZF rats presented no
difference in cardiac output compared to lean rats (Figure 2C);
they exhibited a decreased fraction of ejection (Figure 2D).
Importantly, ProvinolsTM enhanced cardiac output in ZF rats
(Figure 2C) and increased the fraction of ejection (Figure 2D) in
comparison to their controls.
In addition, we found that ProvinolsTM significantly decreased
arterial peripheral resistance in ZF rats (Figure 2E), while the systolic
blood pressure remained the same in both groups of rats (Figure 2F).
ProvinolsTM improve endothelial function in both aortas
and small mesenteric arteries (SMA) from ZF rats
Endothelial dysfunction, which is a key early factor in the
development of atherosclerosis and a predictor of cardiovascular
events, has been found in patients with obesity and metabolic
syndrome [5,25]. Thus, we evaluated the endothelial function in
both conductance (aorta) and resistance (SMA) arteries from ZF
rats and evaluated the potential protective effect of ProvinolsTM.
As shown in Figure 3A, aortic rings from ZF rats had reduced
endothelium-dependent vasodilator responses to Ach compared to
aortic rings from lean controls. Interestingly, ProvinolsTM
significantly corrected this impairment in endothelium-dependent
relaxation in aortas from ZF rats (Figure 3A).
In SMA, endothelium-dependent relaxation was the same in all
four groups (Figure 3B). To get further insight in the component
that may be affected upon ProvinolsTM treatment, we analyzed the
effect of pharmacological inhibitors in SMA from ZF rats only.
Interestingly, while ProvinolsTM did not affect the NO-component
of the response to Ach agonist (Figure 3C), it markedly enhanced
its EDHF-component in SMA taken from ZF rats (Figure 3D)
compared to non-treated ZF rats.
Altogether, these findings indicate that ProvinolsTM improve
endothelial function in aortas from ZF rats and in SMA in
response to pharmacological stimuli.
ProvinolsTM increase arterial NO release in ZF rats by
activating eNOS
Given the important role of NO in the mediation of
endothelium-dependent relaxation in vessels, we evaluated here
the molecular pathways implicated to its production upon
ProvinolsTM treatment in different arteries.
Treatment of ZF rats with ProvinolsTM increased NO production
in aorta (Figure 4A), carotid artery (Figure 4B) and SMA
(Figure 4C), suggesting that the improvement in endothelial
Figure 2. ProvinolsTM improve cardiac function in ZF rats. Echocardiography measurements of diastolic left ventricular dimension (LVDd),
systolic left ventricular dimension (LVDs), cardiac output and fraction of ejection (A–D). Systolic blood pressure was evaluated using tail-cuff
technique (E). Total arterial peripheral resistances were calculated from blood pressure and cardiac output (F). Values are means6SEM (n=6).
*P,0.05 Zucker fatty (ZF) rats vs. lean rats; #P,0.05 ZF+ProvinolsTM rats vs. ZF rats.
doi:10.1371/journal.pone.0005557.g002
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function observed in these arteries is associated with a higher bio-
availability of NO. In order to assess the mechanism(s) of NO
release, we studied the NO signaling pathway in rat aorta. Although
the ProvinolsTM treatment did not modify either expression
(Figure 4D) nor phosphorylation of eNOS at the inhibitor site
(Thr 495, Figure 4E), it significantly enhanced its phosphorylation at
the activator site (Ser 1177, Figure 4F), suggesting that ProvinolsTM
enhanced eNOS activity. Importantly, ProvinolsTM reduced
expression of caveolin-1 (Figure 4G), a protein known to inactivate
eNOS by cell membrane sequestration.
ProvinolsTM decrease arterial O2
2 release in ZF rats by
decreasing the expression of the Nox-1 subunit of
NADPH oxidase
Oxidative stress, which is one of the causative factors of
endothelial dysfunction, is thought to play a major role in the
occurrence and complications of obesity and metabolic syndrome
[26]. Hence, we evaluated the vascular production of O2
2 in ZF
rats and its modulation by ProvinolsTM treatment.
EPR study demonstrated that ProvinolsTM significantly reduced
O2
2 production in aorta (Figure 5A), carotid arteries (Figure 5B)
and SMA (Figure 5C) from ZF rats, indicating a decrease in
oxidative stress favorable to an increase in NO bio-availability.
We evaluated the expression of membrane subunits of NADPH
oxidase (Nox-1, Nox-2 and Nox-4), a major source of cellular O2
2,
in aortas from ZF rats. ProvinolsTM treatment reduced the
expression of Nox-1 subunit (Figure 5D) without affecting that of
Nox-2 or Nox-4 (Figure 5E, 5F). To evaluate the effect of
ProvinolsTM on the vascular capacity to dismutate O2
2, we
examined expression of different isoforms of superoxide dismutase
(SOD). ProvinolsTM did not significantly modify Mn-SOD, Cu/
Zn-SOD or Ec-SOD expressions (Figure 5G–5I).
Discussion
In the present study, we demonstrate that ProvinolsTM leads to an
improvement of glucose and lipid metabolism in ZF rats, enhances
cardiac function and decreases peripheral resistance. In addition,
ProvinolsTM improves endothelium-dependent relaxation in both
aorta and SMA from ZF rats and this is accompanied with an
increase of vascular NO production and with a decrease of O2
2
release, resulting in an increase of NO bioavailability. These effects
are associated with an increase in eNOS activity, and a decrease in
caveolin-1 expression, in addition to a decreased expression of Nox-
1 NADPH oxidase subunit. Interestingly, these results show that
ProvinolsTM leads to an overall improvement of obesity-associated
alterations, including glucose and lipid metabolism, as well as
endothelial and cardiac functions, by mechanisms not related to
those linked to a decrease of body weight gain in ZF rats.
Here, we provide evidence that ProvinolsTM treatment was
effective in acting on the parameters linked to insulin resistance
Figure 3. ProvinolsTM improve endothelial function in ZF rats. Acetylcholine (Ach)-induced relaxation in rat aorta (A), small mesenteric
arteries (SMA) (B), SMA in the presence of inhibitors of EDHF and COX components (C) (apamine, APA; charybdotoxin, CTX; indomethacin, INDO), SMA
in the presence of inhibitors of NO and COX components (D) (INDO, L-NAME). Results are expressed as a percentage of relaxation. Values are
means6SEM (n= 6). *P,0.05, ***P,0.001 Zucker fatty (ZF) rats vs. lean rats; #P,0.05, ###P,0.001 ZF+ProvinolsTM rats vs. ZF rats.
doi:10.1371/journal.pone.0005557.g003
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(glucose and fructosamine levels) in ZF rats compared to their lean
littermates. These effects most likely reduced the deleterious
consequences of increased glycaemia, including the formation of
advanced glycosylated end products that not only increase oxidative
stress but also induce endothelial dysfunction. In accordance with
the present study, other compounds, such as resveratrol, present in
red wine exhibit hypoglycaemic effects in streptozotocin-induced
diabetic rats [27] and in obese ZF rats [28]. Moreover, Napoli et al.
[29] showed that red wine consumption improves insulin resistance
in type 2 diabetic patients.
With regard to lipid lowering properties of ProvinolsTM, the
present study shows that ProvinolsTM reduced circulating
triglycerides and total cholesterol levels, as well as the ratio
between LDL- and HDL-cholesterol in ZF rats compared to lean
controls. Some animal studies suggest that polyphenols may
reduce cholesterol absorption due to the interaction of these
compounds with cholesterol carriers and transporters present
across the brush border membrane [30,31]. Very recently, Rivera
et al. [28] have shown that long-term resveratrol administration
reduces plasma cholesterol and triglyceride levels in ZF rats. Also,
Vinson et al. [32] reported that red wine polyphenol compounds
or grape juices reduce the plasma concentration of lipids in
hamsters. This is consistent with the study in humans, in which
short-term ingestion of purple grape juice has been shown to
reduce LDL susceptibility to oxidation in patients with coronary
artery disease [33]. Indeed, consumption of red wine also reduces
LDL oxidation leading to limited plaque formation in humans
[34]. LDL oxidation was not assessed here but we clearly
demonstrated that ProvinolsTM improves the balance between
LDL- and HDL-cholesterol in obese rats.
In regards to the structure and function of the left ventricle of
ZF rats, we showed that ProvinolsTM reduced the LVDs without
affecting the LVDd and thus improved fractional shortening. Lee
and coworkers [35] suggested that ZF rats exhibited reduced
LVDs and LVDd compared to their lean littermates; however, the
fractional shortening was not different amongst the two groups.
The improvement in LVDs and fractional shortening induced by
ProvinolsTM was also accompanied with an increase in fraction of
ejection and cardiac output, illustrating an improvement in systolic
function. In addition, ProvinolsTM reduced total arterial periph-
eral resistance leading to the absence of modification in blood
pressure. Altogether, these findings highlight the beneficial effects
of ProvinolsTM on cardiac function inasmuch cardiomyopathic
changes are noted in obesity although it cannot be isolated and
attributed to any specific factor, such as volume overload,
oxidative stress, blood pressure changes, or other unclear factors.
Endothelial dysfunction and hypertension are closely related to
obesity and/or insulin resistance [36]. Although many studies
reported that the endothelium-dependent relaxation in response to
Ach is paradoxically preserved or even enhanced in ZF rats
relative to their lean littermates [37], impaired Ach-induced
vasodilatation has also been described [38]. Numerous investiga-
tions have indicated that red wines, grape juices, red wine
polyphenolic and grape skin extracts are potent endothelium-
dependent vasodilators [9,10,39]. Herein, we demonstrated that
the Ach-induced relaxation was impaired in aortas from ZF rats
compared to lean controls, and importantly was completely
corrected by ProvinolsTM treatment. This improvement in
endothelial function was attributable to the increase in NO bio-
availability as given by the concomitant increase in NO and
decrease in O2
2 releases in vessels taken from ProvinolsTM-treated
ZF rats compared to non-treated ZF rats. In accordance with our
previous study [40], ProvinolsTM treatment enhanced activity of
eNOS and decreased the expression of caveolin-1, a protein
known to sequestrate eNOS. In addition, we showed here that
ProvinolsTM decreases NADPH oxidase Nox-1 subunit expression,
leading to a decrease in O2
2 release from aorta. In agreement with
our data, Sarr et al. [41] reported that red wine polyphenols
prevented the angiotensin II-induced expression of Nox-1 subunit
in rat aorta.
Figure 4. ProvinolsTM increase NO vascular release in vessels from ZF rats. NO production in aorta (A), carotid arteries (B) and small
mesenteric arteries (C) from Zucker fatty (ZF) and ZF+ProvinolsTM rats. Values are expressed as units of amplitude (A)/mg weight of dried tissue (dw).
Western blots revealing expression of eNOS (D), phosphorylation of eNOS at Thr495 (E), and NOS Ser1177 (F) and expression of caveolin-1 (G) in aorta
expressed as arbitrary units (A.U.). (n=6). *P,0.05, **P,0.01 vs. ZF rats.
doi:10.1371/journal.pone.0005557.g004
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Of note is that increased EDHF component was highlighted in
response to Ach-induced vasodilatation (chemical stimulation),
although no difference among the groups has been observed in
SMA. Blockade of COX and EDHF components using INDO
and charybdotoxin plus apamin, reduced the response to Ach in
both groups of ZF rats to the same extent, even though the bio-
availability of NO was increased in vessels from ProvinolsTM-
treated animals, suggesting that the amount of NO released in
non-treated ZF rats is sufficient to induce the maximal effect.
Interestingly, when the NO and COX components were inhibited
using INDO and L-NAME, the endothelium-dependent relaxa-
tion in response to Ach was decreased in ZF versus ProvinolsTM-
treated ZF rats suggesting that ProvinolsTM treatment increases
EDHF-mediated relaxation in SMA. Previous studies have shown
that red wine polyphenols induced EDHF-dependent relaxation in
porcine coronary arteries [39,42]. These results underlined an
increased EDHF contribution on Ach response upon ProvinolsTM
after blockade of both NO and COX pathways as a possible
compensatory mechanism in the same way to those shown in our
previous studies in human resistance arteries [43].
The treatment of metabolic diseases and obesity-related
complications are currently based on the treatment of their
individual components, e.g. hypertension and insulin resistance.
Due to the multi-factorial properties of ProvinolsTM, they may be
a good candidate for prevention and treatment of metabolic
syndrome and reduction of cardiovascular risk. Our present study
provides strong evidence for beneficial effects of red wine
polyphenols on both, vascular and cardiac functions in ZF rats,
suggesting that they may therefore be of therapeutic benefit in the
future and may represent a new class of medicinal products against
obesity-associated diseases.
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